Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation :
a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals. In the context of the current opioid crisis, we aim to become the key player of reference in the pain field, through the design and proposition of new active pharmaceutical ingredients based on the development of first-in-class polypeptides derived from TAFA4.
Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein that modulates the transmission of pain information to the brain.
Tafalgie Therapeutics has developed and identified other new drug candidates.
Tafalgie Therapeutics has formed a scientific committee and a supervisory board to assist its management team and the founding partners.
Become the leader in the field of analgesia with a full range of solutions in a market expected to reach $100bn by 2030.
Provide patients with high-efficacy, high-tolerability, and non-addictive drugs for acute severe pain, as well as for prevention and treatment of chronic refractory pain, in a context marked by the opioid crisis.
surgical interventions are performed annually
undergoing surgery experience pain
people in Europe suffer from chronic pain.
do not receive appropriate treatment for their pain.
“ Pain is considered to be the root cause of almost two thirds of medical consultations. For this reason, it is the subject of many studies, both fundamental and clinical.
Active research on this subject IS absolutely essential to improve our understanding of the mechanisms involved in pain and for the development of new treatments. ”
Aziz Moqrich explains to Thierry Lhermitte (France Inter) how pain is modulated in the human body.
Alain Eschalier (MD, PhD, PharmD) is Professor Emeritus of Medical Pharmacology at the University of Clermont, Auvergne, France and is board-certified in pharmacology, psychiatry and human biology.
Dr. Clifford J. Woolf was born in South Africa, where he earned his MB, BCh, and PhD degrees. He then moved to London and became Professor of Neurobiology at University College London. In 1997, he was recruited by the Massachusetts General Hospital and Harvard Medical School to serve as the Richard J. Kitz Professor of Anesthesiology Research.
His research focuses on the roles of the functional, chemical and structural plasticity of neurons in both the normal adaptive functions of nervous systems and in the maladaptive changes contributing to neurological diseases. He focuses, in particular, on pain, regeneration and neurodegeneration and on the exploitation of stem cell-derived neurons for disease modeling and drug screening.
Jean-Louis Kraus is Professor Emeritus at the University of Aix Marseille, France and was formerly Professor at McGill University in Montreal, Canada.
Prof. Kraus’s considerable experience and commercial success have enabled him to develop extensive networks during the course of his career.
• Prof. Levine’s research focuses on pain and analgesia, including, in particular, the mechanism by which the placebo effect can relieve pain. In 1978, he published an influential study showing that placebo analgesia could be blocked by the opioid antagonist naloxone.
His research has led to the identification of new ion channels and receptors activated by temperature, mechanical force, and increases in cell volume. His laboratory has shown that these ion channels play crucial roles in sensing temperature, touch, and pain, in proprioception, and in regulating vascular tone.
Patapoutian was born in Lebanon in 1967 and attended the American University of Beirut for one year before emigrating to The United States in 1986. He became a US citizen, graduating from UCLA in 1990 and obtaining a PhD from Caltech in 996, for his work in the laboratory of Dr. Barbara Wold.
Following his postdoctoral work with Dr. Lou Reichardt at UCSF, he joined the Scripps Research Institute faculty in 2000, and is currently Professor in the Department of Neuroscience. He also held a position at the Genomics Institute of The Novartis Research Foundation from 2000-2014.
Patapoutian was awarded the Young Investigator Award from the Society for Neuroscience in 2006 and was named an Investigator of the Howard Hughes Medical Institute in 2014.
He is a fellow of the American Association for the Advancement of Science (2016), a member of the National Academy of Sciences (2017) and a member of the American Academy of Arts and Sciences (2020). He received the 2017 Alden Spencer Award from Columbia University (together with David Ginty), the 2019 Rosenstiel Award for Distinguished Work in Basic Medical Research (with David Julius), the 2020 Kavli Prize in Neuroscience (with David Julius), the 2021 BBVA Foundation Frontiers of Knowledge Award (shared with David Julius), and the 2021 Nobel Prize in Physiology or Medicine (with David Julius).
2021 : Nobel Prize in Physiology or Medicine (with David Julius)